Literature DB >> 18085512

Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry.

Juliann E Kosovec1, Merrill J Egorin, Susanna Gjurich, Jan H Beumer.   

Abstract

5-Fluorouracil (5-FU) has long had a place in the treatment of many malignancies. 5-FU plasma concentrations have been correlated with toxicity and efficacy, and therapeutic drug monitoring has been reported to result in an improved response/toxicity balance. We report validation, according to FDA guidelines, of a hydrophilic interaction chromatography (HILIC) liquid chromatography/tandem mass spectrometry (LC/MS/MS) assay for the sensitive, accurate and precise quantitation of 5-FU in human plasma. The assay employed an isotopically labeled 5-FU internal standard and ethyl acetate extraction. Separation was achieved with an amino column and an isocratic mobile phase of 0.1% formic acid in acetonitrile/water (97:3, v/v), followed by a wash. Detection consisted of electrospray, negative-mode ionization tandem mass spectrometry in the multiple reaction monitoring (MRM) mode. The accuracy was 96.0-102.2%, and precision was 2.1-7.5% in the concentration range of 10-10 000 ng/mL. Recovery from plasma was 46.0-72.6%, and ion suppression was 9.8-25.7%. Plasma freeze/thaw stability was 87.5-104.3%, and stability for 4 h at room temperature was 98.7-100.0%. This assay is currently being used to quantitate 5-FU in human plasma samples. Copyright (c) 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18085512     DOI: 10.1002/rcm.3362

Source DB:  PubMed          Journal:  Rapid Commun Mass Spectrom        ISSN: 0951-4198            Impact factor:   2.419


  16 in total

1.  In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion.

Authors:  Heidi Colville; Ryan Dzadony; Rebecca Kemp; Stephen Stewart; Herbert J Zeh; David L Bartlett; Julianne Holleran; Kevin Schombert; Juliann E Kosovec; Merrill J Egorin; Jan H Beumer
Journal:  J Extra Corpor Technol       Date:  2010-03

2.  Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring.

Authors:  Daniel Kozo; Matt W Ross; Justin Jarrah; Michael Barrett; Rebecca L Harney; Jodi B Courtney; Irina Baburina; Julianne L Holleran; Jan H Beumer; Godefridus J Peters; Richard J Honeywell; Salvatore J Salamone
Journal:  Ther Drug Monit       Date:  2017-06       Impact factor: 3.681

Review 3.  Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy.

Authors:  Jan H Beumer; Edward Chu; Carmen Allegra; Yusuke Tanigawara; Gerard Milano; Robert Diasio; Tae Won Kim; Ron H Mathijssen; Li Zhang; Dirk Arnold; Katsuki Muneoka; Narikazu Boku; Markus Joerger
Journal:  Clin Pharmacol Ther       Date:  2018-09-11       Impact factor: 6.875

4.  A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.

Authors:  Jennifer R Eads; Jan H Beumer; Lavinia Negrea; Julianne L Holleran; Sandra Strychor; Neal J Meropol
Journal:  Cancer Chemother Pharmacol       Date:  2015-12-21       Impact factor: 3.333

5.  Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma.

Authors:  James D Byrne; Mohammad R N Jajja; Allison N Schorzman; Amanda W Keeler; J Christopher Luft; William C Zamboni; Joseph M DeSimone; Jen Jen Yeh
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-08       Impact factor: 11.205

6.  Pharmacokinetic application of a bio-analytical LC-MS method developed for 5-fluorouracil and methotrexate in mouse plasma, brain and urine.

Authors:  Vaishnavi Ganti; Ellen A Walker; Swati Nagar
Journal:  Biomed Chromatogr       Date:  2013-03-12       Impact factor: 1.902

7.  Pharmacokinetic and Pharmacodynamic Analyses of 5-Fluorouracil in East-Asian Patients with Nasopharyngeal Carcinoma.

Authors:  Yuxiang Ma; Yuehao Lin; Benyan Zou; Wanli Liu; Yang Zhang; Liping Zhao; Yan Huang; Yunpeng Yang; Wenfeng Fang; Yuanyuan Zhao; Jin Sheng; Tao Qin; Zhihuang Hu; Salavatore J Salamone; Yunying Li; Li Zhang; Hongyun Zhao
Journal:  Clin Pharmacokinet       Date:  2016-10       Impact factor: 6.447

8.  A phase I trial of isolated hepatic perfusion (IHP) using 5-FU and oxaliplatin in patients with unresectable isolated liver metastases from colorectal cancer.

Authors:  D Magge; A H Zureikat; D L Bartlett; M P Holtzman; H A Choudry; J H Beumer; J F Pingpank; J L Holleran; S Strychor; D E Cunningham; H L Jones; H J Zeh
Journal:  Ann Surg Oncol       Date:  2013-04-11       Impact factor: 5.344

9.  Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD.

Authors:  Tristan M Sissung; Lisa Cordes; Cody J Peer; Shruti Gandhy; Jason Redman; Julius Strauss; William D Figg
Journal:  Pharmacogenomics       Date:  2020-12-11       Impact factor: 2.533

Review 10.  A Critical Review on Clinical Application of Separation Techniques for Selective Recognition of Uracil and 5-Fluorouracil.

Authors:  Khushaboo Pandey; Rama Shankar Dubey; Bhim Bali Prasad
Journal:  Indian J Clin Biochem       Date:  2015-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.